Company profile: Prolong Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical products and development technologies, including PP-007 (Sanguinate), a PEGylated carboxyhemoglobin bovine product designed to deliver oxygen and carbon monoxide to hypoxic tissues to restore homeostasis and reduce inflammation, and PEGfinity, a PEGylation-based process that enhances the function and stability of therapeutic proteins.
Products and services
- Biopharmaceutical Product Development and Marketing: Develops and markets biopharmaceutical products treating various diseases, biopharmaceutical focus
- PEGfinity: PEGylation-based drug development process that enhances function and stability of therapeutic proteins using PEGylation technique
- PP-007 (Sanguinate): PEGylated carboxyhemoglobin bovine product engineered to deliver oxygen and carbon monoxide to hypoxic tissues to restore homeostasis and reduce inflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prolong Pharmaceuticals
Corridor Pharmaceuticals
HQ: United States
Website
- Description: Provider of platform-based pulmonary and critical care therapeutics, developing and commercializing small-molecule inhibitors of arginase to address elevated arginase levels, targeting arginase—an enzyme that competes with endothelial nitric oxide synthase for l-arginine and leads to ornithine production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corridor Pharmaceuticals company profile →
Glycotope
HQ: Germany
Website
- Description: Provider of GMP-compliant contract manufacturing for active biopharmaceutical ingredients (proteins and antibodies) via recombinant production, and oncology antibody solutions including GT-001 (Lewis Y), GT-002 (LYPD3), GT-00A (MUC1) and an IL-15 immuno-cytokine, plus GlycoTarget Discovery and a platform enabling high tumor-specificity by targeting tumor-associated carbohydrates for ADC/CAR development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycotope company profile →
EdenRoc Sciences
HQ: United States
Website
- Description: Provider of holding and operating services for bioscience and pharmaceutical startups, managing Metro International Biotech (proprietary NAD boosters), Cantata Bio (NGS-based multiomics tools via Dovetail Genomics and Arc Bio), Claret Bioscience, Astrea Forensics (advanced DNA for casework), Delavie Sciences (consumer care ingredients), and Liberty Biosecurity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EdenRoc Sciences company profile →
The Medicines Company
HQ: United States
Website
- Description: Provider of innovative, cost-effective medicines to the worldwide hospital marketplace, focused on advancing treatment of critical care patients. Markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full The Medicines Company company profile →
Plexxikon
HQ: United States
Website
- Description: Provider of small molecule pharmaceuticals focused on discovering and developing therapies for human diseases. Portfolio includes Zelboraf for BRAF V600E–mutant skin cancer, Turalio for tenosynovial giant cell tumor (TGCT), and personalized medicines. Pipeline candidates include PLX204 for diabetes, PLX4032 for melanoma and colorectal cancer, and PLX5568 kinase inhibitors for pain and polycystic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Plexxikon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prolong Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prolong Pharmaceuticals
2.2 - Growth funds investing in similar companies to Prolong Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prolong Pharmaceuticals
4.2 - Public trading comparable groups for Prolong Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →